Evaxion A/S
EVAX
$4.16
-$0.01-0.24%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/12/2026
-
Globe Newswire
5/11/2026
-
TipRanks Financial Blog
5/7/2026
-
Globe Newswire
5/5/2026
-
The Cerbat Gem
5/4/2026
-
Globe Newswire
5/3/2026
-
The Cerbat Gem
4/27/2026
-
Globe Newswire
4/17/2026
-
Globe Newswire
4/17/2026
-
Globe Newswire
4/16/2026
-
Globe Newswire
4/7/2026
-
Globe Newswire
3/30/2026
-
Globe Newswire
3/19/2026
-
Globe Newswire
3/17/2026
-
Globe Newswire
3/5/2026
-
Globe Newswire
3/5/2026
-
Globe Newswire
3/2/2026
-
Globe Newswire
1/13/2026
-
Globe Newswire
Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week
1/7/2026
-
Globe Newswire
12/19/2025
-
Globe Newswire
12/9/2025
-
ACCESS Newswire
12/6/2025
-
Globe Newswire
11/20/2025
-
Globe Newswire
11/12/2025
-
Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, March 5, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 25 and 29 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
45 53 53 18 50
Address
Dr. Neergaards Vej
Horsholm, 2970
Horsholm, 2970
Country
Year Founded
Business Description
Sector
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial...
more